Trial Profile
A Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VAY736 in Rheumatoid Arthritis Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2018
Price :
$35
*
At a glance
- Drugs Ianalumab (Primary) ; Ianalumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Feb 2018 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2017.
- 29 Nov 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2017.